Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

Author(s):
Donk, N.W.C.J. van de; Casneuf, T.; Cara, A. di; Parren, P.W.; Zweegman, S.; Kessel, B. van; Lokhorst, H.M.; Usmani, S.Z.; Lonial, S.; Richardson, P.G.; Chiu, C.; Mutis, T.; Nijhof, I.S.; Sasser, A.K.
Published
2019
Publication type
Article / Letter to editor
multiple myelomadaratumumabFc gamma receptorsimmunotherapypolymorphisms
Date issued
2019-02-01
Language
English
Publisher
WILEY
Is part of
hdl
1887/121524
doi
10.1111/bjh.15122